What sits beneath the five percent?
Pricing headroom in healthcare depends on who controls the purchase.¹
At one of the supplier’s hospital customers, a clinician may see the value immediately. Procurement may push back on the terms, while the payer determines what gets reimbursed. The equipment might be well regarded, and the hospital can still have little room to pay more.
Previous renewals may make uncomfortable reading during commercial diligence. The last rise might have come with a year-end rebate that gave much of it back. Other contracts could leave prices fixed for another year, delaying earnings already included in the forecast.
Headline pricing ambition and realized uplift can be very different things.
Simon-Kucher’s Global Pricing Study² reveals that businesses across industries realize less than half their intended price increases on average.
A collision of growth assumptions
The supplier also hopes to sell those hospitals more equipment and a premium maintenance package. The forecast includes revenue from both.
Suppose a hospital agrees to the five percent provided maintenance comes at no extra charge. The sales director may have secured a perfectly sensible deal.
The committee, however, has counted the price rise and the service fee in full, and now needs to remove revenue it expected to collect.
A promise to place larger orders could bring a request for a volume discount into the same conversation. Nobody has to dismiss the products or question their value for the growth forecast to come apart. The hospital simply negotiates over the total bill.
Growth initiatives that look independent in a model can collide in a customer negotiation.
And even in-depth customer interviews can miss this.
A purchasing manager may like all three proposals and fully expect to negotiate when the time comes to sign. Yet three encouraging answers do not necessarily add up to one acceptable bill.
How much is already in the price?
Now suppose management’s existing forecast already assumes prices will rise by three percent next year. The investment case then identifies a five percent increase as a value-creation opportunity.
But the full five percent is not additional growth. Three points are already in the plan. Only the remaining two represent potential upside beyond what the buyer is already paying for.
That distinction matters. Delivering the original three percent may still require significant commercial effort, but it should not be counted again as growth created by new ownership.
The remaining two points also need a source, perhaps tighter discounting, or untapped willingness to pay in certain accounts, or a different pricing approach. Whatever the answer, the uplift must be traced back to something the business can actually do differently.
There may also be growth the existing plan has overlooked.
The supplier might have won additional equipment orders at some hospitals, with comparable accounts still buying elsewhere. Those sales give the committee a starting point for judging whether that success can be repeated, allowing for tender delays and the cost of extra sales support.
By now, the investment case may look quite different from the one the committee first saw. Some of the original upside has shrunk. Other opportunities have become more convincing. The total may even be larger.
What has changed is the quality of the case behind it.
Five percent may still be achievable. But before investors pay for that growth, the evidence needs to show where it comes from, what it depends on, and how the business can earn it.